Early Versus Delayed Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2023 Jul 27

PMID 37498446

Authors

Gabriel Katz

Efrat Gur

Joseph Moisseiev

Ari Leshno

Affiliations

Soon will be listed here.

Abstract

Purpose: Central serous chorioretinopathy (CSCR) patients are sometimes referred to Photodynamic Therapy (PDT) with very long-term disease. The purpose of this study was to analyze the results of PDT in CSCR eyes with long-standing disease.

Methods: The medical records of the patients that underwent PDT for CSCR between 2009 and 2019 were reviewed. Cases were divided into two groups based on the duration of disease before PDT treatment: early treatment (3 to 6 months) and delayed treatment (longer than 6 months). The treatment was defined as successful when the subfoveal fluid was absorbed during follow-up.

Results: The PDT treatment was successful in 76% and 77% of eyes in the early and delayed treatment groups, respectively. Both groups showed significant improvement in central retina measurements at the 3-months follow-up which persisted to the last follow-up visit. The visual acuity (VA) at baseline was significantly worse in the delayed treatment group (0.5 ± 0.26 vs. 0.3 ± 0.24, P = 0.042) and improved in both groups but remained low in the delayed treatment group during the study.

Conclusion: We suggest that if CSCR is not spontaneously improving over 3 months the patient should be offered PDT, to prevent VA loss from the long-term presence of subretinal fluid in the macula. PDT is not associated with loss of vision in eyes with chronic CSCR, and can be safely used in eyes with relatively good VA.

Citing Articles

[Treatment of central serous chorioretinopathy in comparison-Micropulse laser versus photodynamic therapy].

Sitnilska V, Brocks U, Tode J, Spital G, Altay L Ophthalmologie. 2025; 122(3):186-195.

PMID: 39920292 DOI: 10.1007/s00347-025-02183-0.

References

You E, Hebert M, Jin T, Bourgault S, Caissie M, Tourville E . Comparing interventions for chronic central serous chorioretinopathy: A network meta-analysis. Surv Ophthalmol. 2023; 68(4):601-614. DOI: 10.1016/j.survophthal.2023.03.001. View

van Dijk E, Feenstra H, Bjerager J, Grauslund J, Boon C, Subhi Y . Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses. Acta Ophthalmol. 2022; 101(2):140-159. DOI: 10.1111/aos.15263. View

Gote J, Singh S, Chhablani J . Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2023; 261(8):2135-2168. DOI: 10.1007/s00417-023-05996-4. View

Silva R, Ruiz-Moreno J, Gomez-Ulla F, Montero J, Gregorio T, Cachulo M . Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2012; 33(2):309-15. DOI: 10.1097/IAE.0b013e3182670fbe. View

Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S . Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2013; 33(2):316-23. DOI: 10.1097/IAE.0b013e318280769c. View

Erikitola O, Crosby-Nwaobi R, Lotery A, Sivaprasad S . Photodynamic therapy for central serous chorioretinopathy. Eye (Lond). 2014; 28(8):944-57. PMC: 4135258. DOI: 10.1038/eye.2014.134. View

Fujita K, Imamura Y, Shinoda K, Matsumoto C, Mizutani Y, Hashizume K . One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014; 122(3):555-61. DOI: 10.1016/j.ophtha.2014.09.034. View

Sheptulin V, Purtskhvanidze K, Roider J . Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2018; 256(11):2027-2034. DOI: 10.1007/s00417-018-4086-6. View

Nicolo M, Desideri L, Vagge A, Traverso C . Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review. Pharmaceuticals (Basel). 2020; 13(10). PMC: 7597965. DOI: 10.3390/ph13100264. View

10.

Nicolo M, Eandi C, Alovisi C, Grignolo F, Traverso C, Musetti D . Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014; 157(5):1033-7. DOI: 10.1016/j.ajo.2014.01.022. View

11.

Kim Y, Ryoo N, Woo S, Park K . Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015; 253(12):2063-73. DOI: 10.1007/s00417-014-2926-6. View

12.

Shiode Y, Morizane Y, Kimura S, Hosokawa M, Kawata T, Doi S . COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2015; 35(12):2498-504. DOI: 10.1097/IAE.0000000000000621. View

13.

Liu H, Yang C, Yang C, Ho T, Lin C, Hsieh Y . Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy. Am J Ophthalmol. 2016; 167:57-64. DOI: 10.1016/j.ajo.2016.04.001. View

14.

Cheng C, Chang C, Peng C . COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2016; 37(2):325-333. DOI: 10.1097/IAE.0000000000001138. View

15.

Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H . Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study. PLoS One. 2017; 12(7):e0181479. PMC: 5524407. DOI: 10.1371/journal.pone.0181479. View

16.

Matuskova V, Vyslouzilova D, Uher M . Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Semin Ophthalmol. 2017; 33(5):690-699. DOI: 10.1080/08820538.2017.1416414. View

17.

Chung C, Chan Y, Li K . Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy. Ophthalmologica. 2018; 240(1):37-44. DOI: 10.1159/000484100. View

18.

van Rijssen T, van Dijk E, Dijkman G, Boon C . Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2018; 256(8):1395-1402. PMC: 6060777. DOI: 10.1007/s00417-018-4003-z. View

19.

Asano K, Asaoka R, Asano S, Azuma K, Inoue T, Obata R . ELONGATED PHOTORECEPTOR OUTER SEGMENT LENGTH AND PROGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2019; 40(4):750-757. DOI: 10.1097/IAE.0000000000002445. View

20.

van Dijk E, Fauser S, Breukink M, Blanco-Garavito R, Groenewoud J, Keunen J . Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018; 125(10):1547-1555. DOI: 10.1016/j.ophtha.2018.04.021. View